Advertisement

Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px
Organisation › Details

Valneva Austria GmbH

Intercell AG is an innovative biotechnology company that develops novel vaccines for the prevention and treatment of infectious diseases with substantial unmet medical needs. Intercell’s vaccine to prevent Japanese Encephalitis is the Company’s first product on the market. The Company’s technology platform includes an antigen-discovery system and human anti-infective monoclonal antibody discovery system, adjuvants and a novel patch-based delivery system (Vaccine Patch, Vaccine Enhancement Patch). Based on these technologies, Intercell has strategic partnerships, including with a number of pharmaceutical companies, with GSK, Novartis, Merck & Co., Inc., sanofi-aventis, and Romark. The Company’s pipeline of investigational products includes a Pseudomonas aeruginosa vaccine candidate (Phase II), a vaccine to prevent Pandemic Influenza combining our Vaccine Enhancement Patch with an injected vaccine (Phase I/II), a vaccine program for S. aureus, which is being developed with Merck & Co., Inc. (Phase II/III), a vaccine candidate for Pneumococcus (Phase I) as well as a combination treatment approach for Hepatitis C (Phase II). A vaccine candidate against infections with C. difficile has entered Phase I clinical trials in 2010. In addition, further products focused on infectious diseases are in pre-clinical development. Intercell is listed on the Vienna stock exchange under the symbol “ICLL” (U.S. level one ADR symbol “INRLY”). *

 

Period Start 1998-01-01 established
Period End 2013-10-17 renamed before
  Group Valneva (Group)
  Predecessor Intercell Austria AG
Product Industry vaccine
Persons Person Lingelbach, Thomas (Intercell 201106– CEO before COO before 2001– Chiron Behring)
  Person 2 Kandera, Reinhard (Hookipa Biotech 201704– CFO before Valneva CFO + Intercell CFO + Deutsche Bank AG)
     
Region Region Wien (Vienna)
  Country Austria
  Street 3 Campus-Vienna-Biocenter
  City 1030 Wien
  Tel +43-1-20620
    Address record changed: 2018-07-24
     
Basic data Employees D: 101 to 500 (2015-09-22)
     
    * Document for �About Section�: Intercell AG. (3/1/11). "Press Release: Intercell Announces Q4 and Preliminary Full Year 2010 Financial Results. Growing Revenues from Ixiaro/Jespect Sales – Significant Net Loss Due to One-time Non-cash Effects". Vienna.
     
   
Record changed: 2017-04-01

Advertisement

Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px

More documents for Valneva (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture EBD Group BIO-Europe 2019 Partnering Report BEU2019 650x80px




» top